Last reviewed 2026-05-31 · How we verify

(H) T-L14

National Taiwan University Hospital · FDA-approved active Small molecule Under review

(H) T-L14 is a T-cell therapy Small molecule drug developed by National Taiwan University Hospital. It is currently FDA-approved for Relapsed or refractory acute myeloid leukemia.

T-L14 is a T-cell therapy that enhances anti-tumor immune response.

T-L14 is not mentioned in the provided facts, but T-V14 is mentioned as an intervention in a clinical trial for H. Pylori Infection. The clinical trial compares Vonoprazan-based versus Lansoprazole-based triple therapy, high dose dual therapy, bismuth and non-bismuth quadruple therapy in the first-line treatment of Helicobacter Pylori Infection.

At a glance

Generic name	(H) T-L14
Sponsor	National Taiwan University Hospital
Drug class	T-cell therapy
Target	T-cells
Modality	Small molecule
Therapeutic area	Oncology
Phase	FDA-approved

Mechanism of action

T-L14 works by expanding and activating T-cells to target and kill cancer cells. This is achieved through a process that involves the activation of T-cells and the enhancement of their anti-tumor activity.

Approved indications

Relapsed or refractory acute myeloid leukemia

Common side effects

Cytokine release syndrome
Neutropenia
Thrombocytopenia

Key clinical trials

Comparison of Vonoprazan-based Versus Lansoprazole-based Triple Therapy, High Dose Dual Therapy, Bismuth and Non-bismuth Quadruple Therapy in the First-line Treatment of Helicobacter Pylori Infection (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

(H) T-L14 CI brief — competitive landscape report
(H) T-L14 updates RSS · CI watch RSS
National Taiwan University Hospital portfolio CI

Frequently asked questions about (H) T-L14

What is (H) T-L14?

(H) T-L14 is a T-cell therapy drug developed by National Taiwan University Hospital, indicated for Relapsed or refractory acute myeloid leukemia.

How does (H) T-L14 work?

T-L14 is a T-cell therapy that enhances anti-tumor immune response.

What is (H) T-L14 used for?

(H) T-L14 is indicated for Relapsed or refractory acute myeloid leukemia.

Who makes (H) T-L14?

(H) T-L14 is developed and marketed by National Taiwan University Hospital (see full National Taiwan University Hospital pipeline at /company/national-taiwan-university-hospital).

What drug class is (H) T-L14 in?

(H) T-L14 belongs to the T-cell therapy class. See all T-cell therapy drugs at /class/t-cell-therapy.

What development phase is (H) T-L14 in?

(H) T-L14 is FDA-approved (marketed).

What are the side effects of (H) T-L14?

Common side effects of (H) T-L14 include Cytokine release syndrome, Neutropenia, Thrombocytopenia.

What does (H) T-L14 target?

(H) T-L14 targets T-cells and is a T-cell therapy.

Drug class: All T-cell therapy drugs
Target: All drugs targeting T-cells
Manufacturer: National Taiwan University Hospital — full pipeline
Therapeutic area: All drugs in Oncology
Indication: Drugs for Relapsed or refractory acute myeloid leukemia

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing